This recombinant monoclonal antibody is developed as a research-grade biosimilar to TMB-365, targeting the CD4 glycoprotein. CD4 is a transmembrane protein predominantly expressed on the surface of T helper cells, regulatory T cells, monocytes, macrophages, and dendritic cells. As a co-receptor for the T cell receptor (TCR), CD4 plays a critical role in adaptive immunity by facilitating MHC class II-restricted antigen recognition and T cell activation. CD4+ T cells are central to immune response coordination, and their dysfunction or depletion is associated with autoimmune diseases, immunodeficiency disorders including HIV/AIDS, transplant rejection, and various inflammatory conditions.
TMB-365 is an established research antibody widely used for investigating CD4-mediated immune processes and T cell biology. This biosimilar provides researchers with a reliable tool for studying T cell differentiation, immune regulation, and disease mechanisms involving CD4+ cell populations. It supports investigations into immunological disorders, infectious disease pathogenesis, and therapeutic development targeting immune modulation. The antibody enables consistent experimental results in diverse immunology research applications.
Email: support@cusabio.com
Distributors Worldwide